At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population.
Oral presentation on the Phase 0 “Trigger” Trial featured interim data on the pharmacodynamics and pharmacokinetics of the investigational PARP inhibitor.
In July 2017, Arizona Senator John McCain was diagnosed with an aggressive form of brain cancer known as glioblastoma. A little more than a year later, Senator McCain passed away.